WHO flags funding shortage risk in Afghanistan
A Taliban security personnel stands guard as Afghan burqa-clad women wait to receive free iftar meals in Kabul. Photo: AFP
The World Health Organization said Monday 80 percent of services that it supports in Afghanistan could shut down by June due to a funding shortage.
The UN health agency said the cash shortfall, which comes amid massive US aid cuts, is tied to a shift in "development aid priorities".
"Without urgent intervention, over 220 more facilities could close by June 2025, leaving an additional 1.8 million Afghans without access to primary health care," WHO said in a statement.
The agency said that 167 such operations have already closed due to a lack of financial support.
"The consequences will be measured in lives lost," said WHO's Afghanistan chief Edwin Ceniza Salvador.
"This is not just about funding. It is a humanitarian emergency that threatens to undo years of progress in strengthening Afghanistan's health system," Salvador added.
WHO has been sounding the alarm since US President Donald Trump signed an executive order withdrawing the United States from the agency.
This pullout and the end of Washington's contributions put at risk the global measles surveillance network, which until now has been entirely funded by Washington.
Afghanistan saw more than 16,000 suspected measles cases and 111 deaths in January and February, according to WHO.
The figures are disputed by the Taliban authorities, who returned to power in 2021 with the ousting of the US-backed government.
The Taliban government is not recognised internationally and relies largely on NGOs, UN agencies and aid donors to keep the health system afloat.
WHO said Afghanistan is also facing "multiple health emergencies", including outbreaks of malaria and dengue.
There are ongoing efforts to vaccinate enough children to eradicate polio, which remains endemic in only two countries: Afghanistan and neighbouring Pakistan
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
5 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Express Tribune
a day ago
- Express Tribune
UN says malnutrition rate among Gaza children triples
A boy in Gaza is fed with food from a community kitchen at the Muwasi camp for displaced Palestinians in Khan Younis on 18 May. PHOTO: AP The rate of children suffering from acute malnutrition in Gaza has nearly tripled since a ceasefire earlier this year when aid flowed more freely, according to data collected by humanitarian groups and released by the UN on Thursday. The report was issued at a time when aid distribution in the Palestinian enclave is under intense scrutiny because of deadly shootings close to the operations of a new US-backed system. After the two-month ceasefire broke down in March, Israel blockaded aid supplies into Gaza for 11 weeks. Israel, which has only partially lifted the blockade since, vets all aid into Gaza and accuses Hamas of stealing some of it – something the group denies. Around 5.8% out of nearly 50,000 children under five who were screened in the second half of May were diagnosed with acute malnutrition. This was up from 4.7% in early May and nearly three times the rate in February during a pause in fighting in the 20-month war between Israel and Hamas, an analysis by a group of UN and other aid agencies known as the nutrition cluster showed. The analysis also reported an increase in severe acute malnutrition cases among childrena life-threatening condition that compromises the immune system. A Palestinian minister reported 29 starvation-related deaths among the children and elderly in just a few days last month. The report stated that the centres to support medical complications from severe cases in north Gaza and Rafah in the south of the enclave have been forced to close, leaving children without access to lifesaving treatment
Business Recorder
2 days ago
- Business Recorder
US-backed Gaza aid group says resumes food distribution
GAZA CITY: The US-backed Gaza Humanitarian Fund said Thursday it had resumed food distribution in the war-torn Palestinian territory, after pausing operations for a day following reports of deadly shootings. 'GHF can confirm that we were open for distribution today,' the group said in an email to AFP, adding it had delivered 1.4 million meals at two sites on Thursday and 8.4 million meals since opening a little over a week ago. The group shut down its distribution centres on Wednesday for what it called 'reorganisation' in an effort to improve its work, after its first week of operations was marred by global criticism. Reports from Gaza that dozens were killed over the course of three days as they attempted to reach the aid centres drew sharp condemnation from the United Nations. The UN and major aid organisations have refused to cooperate with the GHF, citing concerns that it was designed to cater to Israeli military objectives. US vetoes UN Security Council demand for Gaza ceasefire Israel's military has maintained it does not prevent Gazans from collecting aid. But army spokesperson Effie Defrin said on Tuesday that soldiers had fired towards suspects who 'were approaching in a way that endangered' the troops, adding the incident was being investigated. The GHF, officially a private effort with opaque funding, began operations last week after Israel completely cut off supplies into Gaza for more than two months amid a breakdown in negotiations for a ceasefire with Palestinian group Hamas. For decades, the UN agency for Palestinian refugees UNRWA had spearheaded aid distribution in Gaza, with dozens of other organisations participating in efforts to assist the population.
